Rilonacept

( DrugBank: Rilonacept / KEGG DRUG: Rilonacept )


5 diseases
IDDisease name (Link within this page)Number of trials
51Scleroderma1
84Sarcoidosis1
106Cryopyrin-associated periodic syndrome3
IDDisease name (Link within this page)Number of trials
107Juvenile idiopathic arthritis2
266Familial mediterranean fever1

51. Scleroderma


Clinical trials : 740 / Drugs : 813 - (DrugBank : 165) / Drug target genes : 140 - Drug target pathways : 231 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

84. Sarcoidosis


Clinical trials : 196 / Drugs : 261 - (DrugBank : 78) / Drug target genes : 73 - Drug target pathways : 183 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

106. Cryopyrin-associated periodic syndrome


Clinical trials : 57 / Drugs : 38 - (DrugBank : 5) / Drug target genes : 4 - Drug target pathways : 47 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

107. Juvenile idiopathic arthritis


Clinical trials : 500 / Drugs : 338 - (DrugBank : 52) / Drug target genes : 65 - Drug target pathways : 157 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

266. Familial mediterranean fever


Clinical trials : 39 / Drugs : 44 - (DrugBank : 6) / Drug target genes : 14 - Drug target pathways : 59 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries